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ABSTRACT 
Background: Smoking is associated with a more severe disease course in people with 
multiple sclerosis (MS). The magnitude of effect of smoking cessation on MS 
progression is unknown. The aim of this study was to quantify the impact of smoking 
cessation on reaching MS disability milestones. 
Methods: This is a cross-sectional study with retrospective reports. A comprehensive 
smoking questionnaire was sent to 1270 patients with MS registered between 1994 and 
2013 in the Nottingham University Hospital MS Clinics database. Demographic and 
clinical data were extracted from the clinical database. Cox proportional hazard 
regression was used to estimate effects of smoke-free years on the time to Expanded 
Disability Status Scale (EDSS) scores 4.0 and 6.0. MS Impact Scale 29 (MSIS-29) and 
Patient Determined Disease Steps (PDDS) were used to assess the physical and 
psychological impact of smoking. 
Results: Each ‘smoke-free year’ was associated with 0.96 (95% CI: 0.95 to 0.97) times 
decreased risk of reaching EDSS 4.0 and 0.97 (95%CI: 0.95 to 0.98) times decreased 
risk of reaching EDSS 6.0. Non-smokers showed a significantly lower level of 
disability in all the self-reported outcomes compared with current smokers.  
Conclusion: The reduction in the risk of disability progression after smoking cessation 
is significant and time-dependent. The earlier the patients quit, the stronger the 
reduction in the risk of reaching disability milestones. The quantitative estimates of the 
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impact of smoking cessation on reaching disability milestones in MS can be used in 
interventional trials.  
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IMPLICATIONS 
This study provides for the first time quantitative estimates of the effects of smoking 
cessation in MS, essential for informing smoking cessation trials. 
The clear effect of smoking cessation on MS progression suggests the need to consider 
adjusting for smoking cessation when assessing for treatment effects in clinical trials of 
treatments for MS. 
Smoking cessation should be an early intervention in people with MS. 
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INTRODUCTION 
Multiple Sclerosis (MS) is a chronic, disabling neurological condition with a 50% 
higher risk to occur in tobacco smokers1,2. This increased susceptibility to MS in 
smokers declines after smoking cessation3. Continuing smoking after the onset of MS 
worsens the clinical course4. Smokers with MS have more severe disease5,6 and 
increased risk of reaching higher disability scores in a shorter time than non-smokers7,8. 
Smoking cessation is beneficial in MS4,8, but the impact on reaching disability 
milestones has not yet been quantified. There is typically a delay between the time a 
preventive measure is instituted and the time positive changes become discernible9. 
How the number of smoke-free years relates to MS progression (the degree of 
reduction in the risk of progression in those who quit) is unknown. In this study we 
address this point.  
We previously reported that patients who stopped smoking, whether before or after MS 
onset, have significantly lower risk of disability progression compared with those who 
continued to smoke4. A recent Swedish study showed a reduction in the time to 
secondary progressive MS in those who continued to smoke compared to those who 
quit smoking shortly after the diagnosis of MS8. However, those studies do not quantify 
the effect of smoking cessation on reaching MS relevant disability scores. Here we 
quantify this impact and aim to provide numbers for sample size calculations in 
smoking cessation trials. 
Patient-based outcomes are increasingly used in the assessment of treatment 
interventions in MS. D'Hooghe et al.10 used a self-reported assessment of disability 
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based on Expanded Disability Status Scale (EDSS)  and on the Disease Steps scale and 
showed that smoking was associated with higher risk of reaching EDSS 6.0 (i.e. 
requiring a walking aid to walk about 100m with or without resting) in relapsing-
remitting MS (RRMS)10. There are no data on the impact of smoking in current, ex- 
and non-smokers with MS and the effects of smoking on the physical and 
psychological MS dimensions, from the perspective of patients. 
Here, we study the effect of smoke-free years on MS disability milestones and we 
assess the impact of smoking on physical and psychological patient-reported outcomes 
in a large clinic-based MS population. In particular, we examine the impact of smoking 
cessation after disease onset on disability progression. 
METHODS 
We performed a questionnaire-based, cross-sectional study with retrospective reports, 
assessing the status and history of smoking; and the impact of smoking on physical and 
psychological dimensions of self-reported outcomes in a specialist clinic-based MS 
patient population  
Setting: 
We used demographic and clinical data from patients registered in the Nottingham 
University Hospital MS Clinics database between 1994 and 2013. These clinics cover 
over 3000 patients and are major catchment and referral centres in East Midlands UK. 
The centre and patient population have been described in more detail elsewhere4,11. 
Data regarding sex, age at last disability assessment, age at MS onset, clinical course 
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(relapsing-remitting-RRMS; secondary progressive-SPMS; and primary progressive-
PPMS),duration of exposure to disease modifying treatments (DMTs), and disability as 
measured by EDSS12 were obtained from the clinical database. EDSS is a disability 
scale, described below. This database includes on average four EDSS scores per 
patient. These were estimated by a neurologist during clinic visits. 
Exposure and Outcomes: 
Smoking: In 2013, a comprehensive smoking questionnaire with questions obtained 
from the Health Survey for England 2010, Respiratory Health (NS)13 and European 
Community Respiratory Health Survey II (ECRHS)14 was sent to 1270 patients with 
MS fulfilling the McDonald and/or Poser criteria15,16. Patients were eligible to 
participate if they were ≥18 years old at the time of study, had clinically definite MS 
and their residence details were available. Detailed data regarding individual smoking 
status and history were obtained. Patients were asked about the age when they started 
smoking regularly, the age when they cut down or stopped smoking, and the intensity 
of smoking (average number of cigarettes smoked per day). Regular smoking was 
defined by the European Community Respiratory Health Survey II criteria 14 as ≥20 
packs of cigarettes or 12 oz (360 g) of tobacco in a lifetime, or ≥1 cigarette per day or 1 
cigar per week for 1 year, and confirmation of smoking within the past month. 411 
patients had been included in our previous work4. Patients were grouped as non-
smokers, ex-smokers or current smokers.  
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Outcome Measures 
Data needed to calculate the time to disability milestones EDSS 4.0 (can walk without 
aid or rest for 500 m) and 6.0 (requires aid to walk about 100 m with or without resting) 
12 were extracted from the clinical database. The EDSS scale ranges from 0 to 10 in 
increments of 0.5 units that mean higher levels of disability 12. The EDSS steps 1.0 to 
4.5 refer to people with MS who can walk without any aid, while steps 5.0 to 9.5 are 
defined by the impairment to walking 12. The EDSS steps 4 and 6 are established 
milestones in clinical studies. 
The physical and psychological impact of MS from patients’ perspective were assessed 
using Multiple Sclerosis Impact Scale-29 (MSIS-29)17 and Patient Determined Disease 
Steps (PDDS)18 which are validated patient-based outcome measures. MSIS-29 
accounts for MS impact on physical (twenty items) and psychological (nine items) 
dimensions 17. Responses use a 5 point Likert type scale range from 1 to 5 (Not at all,  
A little,  Moderately, Quite a bit,  Extremely)17. The total score is the sum of points for 
all 29 questions (minimum score: 29; maximum score: 145)17. A change of ≥8 points in 
MSIS-29 (0 to 145 scale) is thought to reflect clinical change 19. A higher score 
corresponds to more disability. We used the average score (the overall score divided by 
29) which considers the number of questions that patient has answered, as we used 
previously 20. The corresponding minimally clinically meaningful change on the scale 
used (1 to 5) is 0.27. 
PDDS is a patient-reported outcome measure that reflects motor disability18 and 
focuses on how well the patients walk. It has nine ordinal levels ranging between 0 
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(normal) and 8 (bedridden) of which the patient chooses the one that best describes his 
situation. PDDS scores can be converted into classifications of mild, moderate, or 
severe disability18,21. PDDS is a surrogate of the EDSS21. The higher score, the greater 
the degree of disability. 
The study was approved by East Midlands Research Ethics Committee Derby-1.  
Statistical analysis 
To test the differences in median MSIS-29 and PDDS scores between smoking groups, 
we used two-sample Wilcoxon rank-sum (Mann-Whitney) and Kruskal–Wallis tests, 
and for testing the difference in proportions of males and females in different smoking 
categories Chi square test was used.  Median regression models were used to compare 
MSIS-29 and PDDS between current, ex- and never-smokers while adjusting for 
disease duration, age at onset, sex, initial course (relapse-onset vs. PPMS) and DMTs 
for ≥1 year. Median regression coefficients are interpreted like ordinary regression 
coefficients. Cox proportional hazard regression models were used to estimate the risk 
of reaching EDSS 4.0 and 6.0. To investigate effects of smoking cessation we fit a 
model with smoke-free years. Final models were adjusted for potential confounders 
including initial course, DMT for ≥1 year, and sex. The time axis for the regression was 
age, with entry from date of MS onset. This ensured hazard ratios for all risk factors 
were adjusted for chronological age. Patients were followed to the first sustained EDSS 
score 4.0 or 6.0 or censored if they had not experienced the outcome by the time of last 
clinic visit, independent of the study end time. We did not correct for multiple 
comparisons as the factors analysed were not independent. 
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When fitting the smoke-free years variable in the model, we only included intensity of 
smoking to avoid collinearity and non-proportional hazard. Only current and ex-
smokers were included in the smoke free-years analysis. The smoke-free years was set 
to 0 for current smokers and the interval between age at the disability milestone (if have 
reached the milestone) or last visit (if censored) and age at smoking cessation in ex-
smokers. For example, if an individual starting smoking at age 22 had MS onset at 33, 
quit smoking at 47, and reached EDSS 6.0 at 55, the smoke-free years was set = 8 and 
smoking duration = 25 years. In models without smoke-free years, pack-years were 
used to adjust for the impact of duration and intensity of smoking. 
Statistical analyses were performed using Stata version 13.1 (StataCorp. 2013. Stata 
Statistical Software. College Station, Texas, USA: StataCorp LP). 
RESULTS 
Patient characteristics 
We originally identified 1412 patients who attended Nottingham university MS specific 
clinics between 2000 and 2013. Of those, 120 were deceased, 14 did not have clinically 
definite MS, eight had missing residential address and eight questionnaires were 
incomplete and were excluded. In all, 680 questionnaires with full data were returned, 
representing a 54% response rate. Mean age was 53 (SD ±11.33) with 2:1 female:male 
ratio. 57% had RRMS, 33% SP MS and 10 % PPMS. Mean MS duration was 19 
(±10.4) years. 54% had ≥1 year of DMT exposure.  
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Smoking prevalence 
 62% of the patients reported they had tried tobacco at some point (ever-smoked), 
however, 51% reported having smoked regularly (regular smokers) and were further 
grouped into current or ex-smokers. At MS onset, 18% and 33% were ex-smokers and 
current smokers, respectively. At the time of the study 35% of smokers had quit 
smoking and 16% were current smokers. The percentages of non-, ex-, and current 
smokers were different between sexes. At the time of study 40 %, 45% and 14% of 
males were non-, ex-, and current smokers vs. 52%, 31% and 16% of females (P = 
0.003). Mean age at the start of smoking was 17.5 (SD ±4.4) years. Smokers smoked 
for an average of 22.7 (±13.4) years with average smoking intensity of 14.6 (±8.7) 
cigarettes/ day. 
MSIS-29 and PDDS scores 
The median MSIS-29 and PDDS scores are shown in table 1. Both the average 
psychological and physical MSIS-29 scales, but not the overall scale, were higher in 
current-smokers compared to ex-smokers, who had higher scores than never-smokers. 
The higher scores reflect a higher level of disability. 
The highest impact of smoking was on the MSIS-29 psychological scale where current 
and ex-smokers had a 0.8 (95%CI: 0.41 to 1.19, P < 0.001) and 0.56 (95%CI: 0.18 to 
0.94 P = 0.004) increase in the median score compared with non-smokers, controlling 
for initial type of MS, disease duration, onset age, sex and exposure to treatment. 
Median overall scores were higher by 0.47 (95%CI: 0.14 to 0.80, P = 0.006) in current 
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smokers and by 0.33 (95%CI: 0.12 to 0.53, P = 0.002) in ex-smokers compared to non-
smokers. The median MSIS-29 physical score was higher in current smokers 
(Coefficient (Coef): 0.58, 95%CI: 0.29 to 0.93, P = 0.001 and in ex-smokers (Coef: 
0.32, 95%CI: 0.02 to 0.61, P 0.03) compared with non-smokers. 
Both current and ex-smokers had higher PDDS scores than non-smokers (Table 1). The 
median adjusted PDDS score was 0.98 (95%CI: 0.53 to 1.43, P < 0.001) higher in 
current smokers compared with non-smokers. Ex-smokers had a non-significant trend 
to a higher median PDDS score compared with non-smokers (Coef: 0.34, 95%CI: -0.05 
to 0.75, P =0.08). Coefficients of differences in median MSIS-29 and PDDS scores 
between non-, ex- and current smokers are shown in Table 2. 
Smoking cessation and the risk of reaching EDSS scores 4.0 and 6.0 
There were no differences in the assessment frequency between smoking groups. 
Patients who smoked between disease onset and the time of EDSS 4.0 and 6.0 had 2.42 
(95%CI: 1.63 to 3.60, P < 0.001) and 1.86 (95%CI: 1.19 to 2.91, P = 0.006) times 
higher risk of reaching these two milestones compared with never-smokers. Total pack-
years smoked up to each milestone showed no significant association with disability 
progression. In smokers, there was a significant difference in age at EDSS scores 4 and 
6 between those who continued to smoke and those who quit smoking. Age at EDSS 
score 4 was 41 (95%CI: 36 to 43) in continuing smokers, 43 (95%CI: 40 to 46) in those 
with 1 to 15 smoke-free years and 52 (95%CI: 48 to 56) in the group with >15 smoke-
free years (P<0.001). The corresponding age for EDSS score 6 was 45 (95%CI: 41 to 
50), 49 (95%CI: 43 to 54) and 55 (95%CI: 50 to 59), respectively (P<0.001) (Figure 2). 
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Each year elapsed from smoking cessation was associated with 0.96 (95%CI: 0.95 to 
0.97, P < 0.001) times decreased risk of reaching EDSS 4.0 and 0.97 (95%CI: 0.95 to 
0.98, P < 0.001) times decreased risk of reaching EDSS 6 (Table 3). For example, an 
ex-smoker who stopped smoking 10 years earlier than a patient who continued smoking 
would have 33% and 26% lower risk of reaching EDSS scores 4.0 and 6.0, respectively 
(calculated as 1-(HR)^10). 
DISCUSSION 
In this study, we provide quantitative measures of the impact of smoking cessation on 
MS progression. These data are novel and can be used in smoking cessation trials in 
MS. We use for the first time ‘smoke-free years’ to quantify the impact of smoking 
cessation on disability progression. We show that each year after smoking cessation 
reduces the risk of reaching disability landmarks and the reduction in the risk of 
reaching advanced disability is greater if implemented early. 
The prevalence of smokers and the intensity of smoking in our population are close to 
those reported in other studies6,22. 16% of the patients in our cohort were current 
smokers at the time of the study, vs. 16.7% in a study on smoking from the North 
American Research Committee on MS (NARCOMS) Registry23, 15.2% in a self-
reported National MS Society Rhode Island Chapter study24 and 14% in a recent 
Swedish study8. Few participants began smoking after MS onset. Many ex-smokers 
quit after disease onset, suggesting that a diagnosis of MS may influence smoking 
patterns, as reported25. In our cohort, the proportion of smokers was higher in males. 
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Although at the time of the study the sex-specific proportion of current smokers was 
close (16.5% in women vs. 14.5% in males), more women were current smokers. 
Smoking in women, could have a bearing on the increasing female:male ratio in MS26. 
In our population, the proportion of smokers at onset of MS was the highest (40%) in 
patients who had already converted to SPMS at the time of the study. The SPMS group 
also had the highest proportion of current smokers. Several factors can account for this. 
Firstly, most people with RRMS will convert over time to SPMS, and continued 
smoking hastens this transition to SPMS6,8. Secondly, people in the SPMS group are 
older than those in the RRMS group, and smoking prevalence was higher in the past 
decades 27. Finally, people with SPMS generally have higher degrees of disability and 
longer disease duration than RRMS, and the use of tobacco could be a coping 
mechanism, as is seen in other chronic diseases28-31. Of note, 1/3 of all patients with 
MS in this study were current smokers at the onset of MS. This high prevalence of 
smoking at onset indicates that many patients are candidates for cessation interventions. 
The data used in this study are novel and come from a well-established cohort of 
patients with MS4. We estimated the risk of reaching EDSS scores of 4.0 and 6.0, 
which are robust outcome measures and milestones of disability in MS. Generally, MS 
patients reaching EDSS 4.0 have already entered secondary progression32. A study by 
Koch et al. used time to EDSS 4.0 and 6.0, however, it did not find significant evidence 
of an association between cigarette smoking and progression33. Differences in sample 
size (364 patients in that study, 680 in ours) and longer follow-up make our estimates 
more robust. Our data are in agreement with those of D'Hooghe et al.10, who showed 
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higher risk of reaching EDSS 6.0 amongst occasional and daily cigarette smokers. 
Importantly, by adjusting for major confounders, we show that the effect of smoking on 
progression is independent of disease duration, age at onset, sex, initial type of MS, and 
DMTs exposure. While total pack-years smoked before each disability landmark were 
not associated with the risk of reaching EDSS 4.0 and 6.0, the smoke-free years had an 
impact on reaching both outcomes. Of note, Hedstrom et al.3 found that the risk of 
developing MS in people who smoke decreases slowly after cessation regardless of the 
dose-response association between smoking and the risk of MS. 
Our findings show that 10 smoke-free years can account for a 33% and 26% lower risk 
of reaching EDSS scores 4.0 and 6.0 in ex-smokers compared to current smokers. 
Interestingly, our estimated risk reduction of 33%, 10 years after smoking cessation, 
confirms the findings by Ramanujam et al.8 and Hedstrom et al.3 and suggests that the 
mechanism responsible for increased susceptibility to MS in smokers also impacts 
disease course after MS onset. The impact of smoking and smoking cessation on 
smoking-related diseases is time-dependent 34. Our findings show that the earlier 
smokers with MS quit, the better the effect on progression in the long term. Data from 
the general population show that recovery after cessation is slow and incomplete. 
Smoking is associated with white matter hyperintensity progression35 and accelerated 
cortical thinning36. Although partial recovery of cortical thinning is possible in ex-
smokers, it takes time36. Epigenetic changes may be involved in the development and 
progression of MS37. Specific methylation status is sensitive and specific for smoking 
status38. Some methylation sites revert to levels typical of never-smokers within 
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decades, but others remain differentially methylated more than 35 years after smoking 
cessation39. 
In this study we showed that the physical and psychological impact of MS from the 
patient perspective is worse in smokers than in non-smokers. MSIS-2917 physical and 
psychological scales measure related but distinct constructs and it was suggested that a 
combined score may mask differential effects on physical and psychological health17. 
In our study, the unadjusted MSIS-29 scores showed an ascending trend from non- to 
current-smokers when physical and psychological scales were measured separately, but 
not for the overall score. 
Overall, smokers fared worse on both physical and psychological MSIS-29 scales and 
on overall scores. The absolute differences in MSIS-29 scores between current- and 
never-smokers are likely to be clinically meaningful (>0.27 points on the MSIS-29 
scale 1 to 5).19 
Interestingly, the highest impact of smoking was noted on the MSIS-29 psychological 
scale. MSIS-29 psychological is more valid for detecting group differences in anxiety 
and depression17 and smoking is associated with increased risk of anxiety and 
depression in people with MS25,40. Our study did not assess if smoking is a marker of 
risk or a causal factor for psychological change. Importantly, despite the belief among 
many smokers that quitting will lead to worsened mental health, smoking cessation is 
associated with reduced anxiety and depression25. 
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Cognitive impairment occurs in approximatively half of all people with MS, and 
typically involves information processing speed, attention, working memory and 
executive functions 41. The MSIS-29 score is a predictor of self-efficacy in MS42, which 
in turn correlates with attention, reaction time variability and speed of memory42. We 
have not assessed cognition in this group of patients. It would be of value in the future 
to consider the influence of smoking on cognition in people with MS. 
Here we show that the scores of the two patient-reported outcome measures MSIS-29 
physical and PDDS were lower in ex-smokers than in current-smokers. We suggest that 
MSIS-29 and PDDS are reliable measures for monitoring of people with MS 
undertaking smoking cessation interventions. MSIS-29 physical has been used in long-
term phase III treatment studies 19. The PDDS, a surrogate of EDSS18, is used in 
clinical research and practice alongside EDSS or when EDSS is impractical or costly18.  
Strengths of this study include the large cohort and the use of validated patient-based 
outcomes with questionnaires previously employed in MS. The main limitations of the 
study include the retrospective design (retrospective reports of smoking status with 
possibility of recall bias), and the low response rate (54%) making generalizability 
uncertain. Another limitation is the lack of biochemical verification of smoking status 
(e.g. exhaled CO or urine nicotine/cotinine) in the participants to the study. The 
response rate in our study is similar to the response rate seen in other population 
questionnaire-based studies in MS 43,44. More of those who did not return the 
questionnaire could have been smokers. Smokers with MS have generally higher levels 
of disability 4which could have precluded them from participating in the study, and 
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smokers from disadvantaged groups tend to participate at lower rate in research studies 
45,46. However, bias due to the response rate is less likely as the group of respondents 
was representative of the population studied (similar rates of smokers, ex- and never 
smokers as the cohort in Manouchehrinia et al.4). Moreover, this study focused on the 
impact of cessation in the respondents and not on the prevalence of smoking in the 
overall MS population. Another limitation is the reliance on self-reported adverse 
health behaviours, which may be susceptible to reporting bias, common to many 
similar studies25 . Also, the cross-sectional assessment of the MS disability with MSIS-
29 and PDDS questionnaires cannot provide information about how the impact of MS 
changes over time. Future studies assessing that impact at different time points could 
address this issue. 
This study is novel in the effort to quantify the effect of smoking cessation. We provide 
for the first time estimates of the likelihood of reduction of progression in MS. These 
data can be used for calculation of sample size and effect size in intervention trials of 
smoking cessation in people with MS. Notably, the clear effect of smoking cessation on 
MS progression suggests the need to consider adjusting for smoking cessation when 
assessing for treatment effects in clinical trials of treatments in MS. 
In conclusion, smoking cessation is associated with a significant reduction of the risk of 
disability progression. Smoking cessation should be an early intervention in people 
with MS. 
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Tables 
Table 1: The median (interquartile range) MSIS-29 and PDDS scores by smoking 
status at the time of study. 
 Never smoked Ex-smokers Current smokers P-value * 
MSIS-29 overall scale 2.72 (1.93-3.48) 3.19 (2.31-3.79) 3.10 (2.31-3.93) < 0.001 
MSIS-29 physical 2.85 (1.95-3.55) 3.25 (2.35-3.95) 3.35 (2.25-4.15) < 0.001 
MSIS-29 psychological 2.33 (1.67-3.32) 2.89 (2-3.67) 3.11 (2.11-3.67) < 0.001 
PDDS 4 (2-6) 5 (3-6) 5 (3-6) 0.02 
* P-values from Kruskal–Wallis one-way analysis of variance for differences between 
never-, ex- and current smokers. 
MSIS-29: Multiple Sclerosis Impact Scale; PDDS: Patient Determined Disease Steps. 
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Table 2: Coefficients of differences in median MSIS-29 and PDDS scores between non-, ex- and current smokers. 
 
 
 
 
 
 
 
 
* Coefficients from median regression models adjusted for disease duration, disease initial phenotype, sex, age at disease onset and exposure to 
disease modifying treatments. MSIS-29: Multiple Sclerosis Impact Scale; PDDS: Patient Determined Disease Steps.  
 
 
 
 
 
 
 
 
 
 
 
Median overall 
MSIS-29 score * 
Median MSIS-29 
physical score * 
Median MSIS-29 
Psychological score * 
Median PDDS score * 
Non-smokers 
Ex-smokers 
Current smokers 
Ref. 
0.33 (0.12 to 0.53) 
0.47 (0.14 to 0.80) 
Ref. 
0.32 (0.02 to 0.61) 
0.59 (0.24 to 0.94) 
Ref. 
0.56 (0.18 to 0.94) 
0.80 (0.42 to 1.19) 
Ref. 
0.35 (-0.05 to 0.75) 
0.99 (0.53 to 1.43) 
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Table 3: Hazard ratios of reaching EDSS scores 4 and 6 
 
 
 
 
 
 
 
† Hazard ratios from Cox regression models adjusted for disease initial phenotype, sex, exposure to disease modifying treatment and pack-years 
smoked.  
‡ Hazard ratios from Cox regression models adjusted for disease initial phenotype, sex, smoking intensity and exposure to disease modifying 
treatments. 
EDSS: Expanded Disability Status Scale. 
 
  
 Hazard of reaching EDSS 4.0 † Hazard of reaching EDSS 6.0 † 
Non-smokers 
Ex-smokers 
Current smokers 
Ref. 
1.09 (0.81 to 1.46) 
2.42 (1.63 to 3.60) 
Ref. 
0.96 (0.69 to 1.32) 
1.86 (1.19 to 2.91) 
Years elapsed from 
smoking cessation ‡ 
0.96 (0.95 to 0.97) 0.97 (0.95 to 0.98) 
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Figure titles  
 
Figure 1. Flow chart of the questionnaires included in the study 
 
Figure 2. Kaplan-Meier plots of age at EDSS scores 4 and 6. P-values from log-ranked 
tests of equality of survival. 
 
